|L - Antineoplastic and Immunomodulating Agents|
This group comprises preparations used in the treatment of malignant neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.
|L01 - Antineoplastic Agents|
Combination products are classified in L01XY - Combinations of antineoplastic agents.
Detoxifying agents used in connection with high dose treatment of antineoplastic agents are classified in V03AF (e.g. calcium folinate).
Radium-223 dichloride used in the treatment of cancer is classified in V10XX.
No DDDs have been established because of highly individualised use and wide dosage ranges. The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.
The consumption of the antineoplastic agents is in some countries measured in grams. This is recommended as a method to be used internationally for these particular agents.
|L01X - Other Antineoplastic Agents|
This group comprises antineoplastic preparations which cannot be classified in the preceding groups.
|L01XC - Monoclonal Antibodies|
Monoclonal antibodies indicated only for the treatment of cancer are classified in L01XC.
Anecortave, indicated for the treatment of exudative age-related macular degeneration, is classified in S01XA - Other ophthalmologicals.
Dinutuximab and dinutuximab beta are classified at the same 5th level..